Structured data verified
Signanthealth
Dropout rates of 15-30% in AOM trials threaten regulatory submissions. Evidence-based strategies to improve participant retention in anti-obesity trials.
What AI can read here
The kinds of structured data found across 23 pages of this site, and how many pages carry each one.
Where to start
- Signant's Clinical & eCOA Science Experts | Leaders in Clinical Trials service
- SmartSignals Clinical Trial Solution Suite | Signant Health homepage
- Reducing Participant Dropout in Anti-obesity Medication Trials homepage
- FDA AI Guidance and COA Validation in Clinical Trials | Signant Health homepage
- Can Dementia Trials Be Decentralized Without Losing Data Quality? webpage
- What eCOA Data Does a Vaccine Trial Actually Need to Capture? webpage
- Can a 10-Item PANSS Work as Well in Pediatric Trials? webpage
- Page not found homepage
- Novel Endpoints in Parkinson's Trials: What Comes After UPDRS? webpage
- Why Do Schizophrenia Trials Fail to Separate Drug from Placebo? webpage
- https://signanthealth.com/resources/pros-for-early-phase-oncology-dose-selection:-full-research homepage
- PROs for Early Phase Oncology Dose Selection: Full Research webpage
- Reducing Participant Dropout in Anti-obesity Medication Trials webpage
- Reasons CNS Trials Fail to Separate Drug from Placebo webpage
- Why Are Wearables and Sensors Still Underused in Clinical Trials? webpage
- Why Do Mood Disorder Trials Enroll the Wrong Participants? webpage
- Are Cancer Trial PROs Actually Measuring Treatment Tolerability? webpage
- Why Oncology Patients Struggle With ePRO and How to Fix It webpage
- https://signanthealth.com/resources/audio-surveillance-of-madrs-interviews:-what-3,736-ratings-reveal homepage
- Why eCOA Is the Cornerstone of Every Decentralized Trial webpage
- How to Select and Adapt Oncology PROMs Under the 2024 FDA Guidance homepage
- ePRO for Older Participants: What the Evidence Actually Shows webpage
- How to Move From Siloed RTSM Studies to Portfolio-Level Operations webpage